Autopsy report · NCT01166178
Zoledronic Acid in MS-patients With Osteoporosis
Cause of deathNo reason given
Life of this trial
- Registered 3 months before it started.
- Ran for about 1 year 8 months before it stopped.
- 29 participants enrolled.
- Results were posted on the registry 1 year 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Novartis
- Sponsor type
- Industry
- Conditions
- Osteoporosis; Multiple Sclerosis
- Interventions
- Zoledronic Acid; Placebo; Calcium and Vitamin D combination
- Participants
- 29
- Sites
- 15
- Countries
- Germany
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.